Economic Evaluation in Genomic and Precision Medicine

Cover image

Title page

Table of Contents

Copyright

Contributors

Preface

Chapter 1: Introduction to economic evaluation in health sciences

Abstract

1.1: Introduction

1.2: Key economic concepts and terminology used in health economics

1.3: Economic evaluation

1.4: Concluding remarks

References

Chapter 2: Foundations of pharmacogenomics and personalized medicine

Abstract

Acknowledgments

2.1: Introduction

2.2: Implementing pharmacogenomics into clinical care

2.3: Electronic tools for translating genomic findings into a clinically meaningful format

2.4: Assessing the ethical, societal, and financial aspects of personalized medicine

2.5: Large-scale personalized medicine implementation efforts worldwide

2.6: Conclusions and future perspectives

References

Chapter 3: Economic evaluation of genome-guided treatment in oncology

Abstract

3.1: Introduction

3.2: Methodological challenges

3.3: The inseparability of test and treatment

3.4: Value of testing

3.5: Cost-effectiveness comparator

3.6: Pricing and reimbursement

3.7: Conclusion

References

Chapter 4: Economic evaluation of rare diseases and the diagnostic odyssey

Abstract

Acknowledgment

4.1: Introduction

4.2: Genomics and rare diseases

4.3: Economic evaluations of genomics in rare diseases

4.4: Conclusion

References

Chapter 5: Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions

Abstract

5.1: Introduction

5.2: Economic evaluation of adverse drug reaction-related human leukocyte antigen genotyping, its guidelines, and current implementations

5.3: Conclusions

References

Chapter 6: Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing

Abstract

Acknowledgments

6.1: Introduction

6.2: Implementing personalized medicine interventions beyond high-income countries: Setting the scene

6.3: Examples of economic evaluations of personalized medicine interventions in medium- and low-income countries

6.4: A generic model as tool for measuring cost-effectiveness of personalized medicine interventions in medium- and low-income countries

6.5: Conclusion and future perspectives

References

Chapter 7: Theoretical models for economic evaluation in genomic and personalized medicine

Abstract

7.1: Introduction

7.2: The genome economics model

7.3: Generalization of the genome economics model

7.4: Perspectives

References

Chapter 8: Using “big data” for economic evaluations in genomics

Abstract

8.1: Introduction

8.2: Using “big data” for the economic evaluation of genomic tests

8.3: Analytics for omics data

8.4: Difficulties in using “big data” in for economic evaluation of sequencing tests

8.5: Conclusions

References

Further reading

Chapter 9: Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting

Abstract

Acknowledgments

9.1: Introduction

9.2: Identifying stakeholders in personalized medicine

9.3: Eliciting and analyzing stakeholder views and opinions related to personalized medicine

9.4: Implementing stakeholder analysis in genomic and personalized medicine: An example from the preliminary assessment of the genomic and personalized medicine environment in Greece

9.5: Defining opportunities and threats when implementing genomic and personalized medicine in Greece

9.6: Concluding remarks

References

Chapter 10: Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions

Abstract

10.1: Introduction

10.2: Institutions involved in pricing and reimbursement

10.3: Coverage, pricing, and reimbursement strategies for genomic testing services

10.4: A proposed strategy for pricing and reimbursement in personalized medicine

10.5: Restrictions and concerns

10.6: Conclusions

References

Index